The extent to which these outcomes might apply to the administration of recombinant human erythropoietin to patients with cancer, treated with chemotherapy to achieve haemoglobin concentrations less than 13 g/ dl, is unclear because few patients with these characteristics were included in the data reviewed.
Mil määral need tulemused võiksid kehtida inimese rekombinantse erütropoetiini manustamisel keemiaravi saavatele vähiga patsientidele, et saavutada hemoglobiini kontsentratsioone vähem kui 13 g/ dl, on ebaselge, kuna nende karakteristikutega patsientide arv oli liiga väike avaldatud andmetes.